TORONTO and AACHEN, Germany, Feb. 5, 2026 /CNW/ - Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, and Grünenthal, a global leader in pain management and related diseases, ...
Bayer is selling its testosterone treatment Nebido to German pharmaceutical firm Gruenenthal in a deal valued up to 500 million euros ($500.95 million), it said on Thursday. BERLIN, July 14 (Reuters) ...
Indevus Pharmaceuticals Inc. gained U.S. rights to Nebido, an injectable treatment for hypogonadism developed and previously launched in Europe by Berlin-based Schering AG. Terms call for Indevus to ...
Shares of Indevus Pharmaceuticals Inc. plunged nearly 70 percent after the company reported at least a two-year setback for Nebido, its three-month formulation of testosterone, for male hypogonadism ...
AACHEN, Germany and TORONTO, Feb. 5, 2026 /PRNewswire/ -- Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical ...
BERLIN, July 14 (Reuters) - Bayer (BAYGn.DE), opens new tab is selling its testosterone treatment Nebido to German pharmaceutical firm Gruenenthal in a deal valued up to 500 million euros ($500.95 ...
Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced they have entered into a licensing ...
Aachen, Germany & Toronto, Canada, February 5, 2026 (News Aktuell) – Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results